Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Terumo to Acquire Vascutek of Scotland
October 21, 2002
- PFSB to Put Top Priory on Post-marketing Safety
October 21, 2002
- Olympus to Provide Contents for WebSurg's Online Telesurgery Training Site
October 21, 2002
- REGULATORY NEWS IN BRIEF
October 21, 2002
- Toshiba Corp, Toshiba Medical: Architect c8000
October 21, 2002
- BULLETIN
October 21, 2002
- DIAGNOSTIC NEWS IN BRIEF
October 21, 2002
- The 61st Annual Meeting of the Japanese Cancer Associarion
October 21, 2002
- 21st IFPMA Assembly Held in Berlin
October 21, 2002
- Communication Is Most Important in Int'l Collaborative Studies: Prof. Uchida
October 21, 2002
- NEW PRODUCTS
October 14, 2002
- DIAGNOSTIC NEWS IN BRIEF
October 14, 2002
- Alcon Japan Aims to Be Leader in Glaucoma Treatment: President Kodama
October 14, 2002
- OTC NEWS IN BRIEF
October 14, 2002
- Korosho to Take Action to Materialize Industry Vision
October 14, 2002
- Yamanouchi Aims at \570 Bil. Sales in FY2004: President Takenaka
October 14, 2002
- Korosho Plan for Healthcare Reform to Be Presented by End of November
October 14, 2002
- Healthcare Expenditures Down 1.6% in 2nd QTR VS 1st QTR
October 14, 2002
- REGULATORY NEWS IN BRIEF
October 14, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 14, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…